https://seekingalpha.com/article/4128751-viking-therapeutics-buy-rumor-buy-news

— — — — —

Viking Therapeutics (VKTX) announced top-line results for its Phase II trial of VK5211 on Nov-28th. Headline data was positive with the study achieving its primary endpoint of demonstrating statistically significant, dose-dependent increases in lean body mass (less head) in all dosage arms, and with zero drug-related serious adverse events (SAEs) being reported.

VK5211 is a powerful selective androgen receptor modulator (SARM) that is being positioned clinically as a potential best-in-class therapy for improving muscle and bone growth. The trial was based around the drug’s initial target indication of elderly patients recovering from a hip fracture – a large, underserved market in which there are approx. 300k hospitalizations per year in the U.S. alone. The trial launched in late 2015 and, after various delays in recruiting patients, was finally completed in summer 2017. The 108-person study was designed to assess increases in lean body mass and was divided into three treatment arms: 0.5mg, 1.0mg, and 2.0mg, as well as a placebo group…

— — —